Bristol-Myers Squibb will no longer make or market Tequin(gatifloxacin) but will not pull current supplies off the market.
Bristol-Myers Squibb will no longer make or market Tequin (gatifloxacin) but will not pull current supplies off the market. The company is returning its rights to Kyorin Pharmaceutical. In February, the FDA and BMS strengthened a warning against the use of Tequin by people with diabetes after reports of problems with high and low blood sugar associated with the drug. The watchdog group Public Citizen has petitioned the FDA to ban the drug, charging that it has caused deaths and hospitalizations.
To see more Hot off the Press news articles, click here click here.
To go to the Drug Topics homepage, click here.
Examining Trends in Long-Term Opioid Use, Importance of Pharmacist-Physician Collaboration
March 27th 2024At APhA 2024, 2 posters looked into how collaboration between physicians and community pharmacists is crucial when it comes to opioid prescriptions, and current opioid use patterns among older adults.